Development of a novel engineered antibody targeting human CD123

详细信息    查看全文

• 作者：Shima Moradi-Kalbolandi^a ; Mahdi Habibi-Anbouhi^a ; ^{habibi_m@pasteur.ac.ir" class="auth_mail" title="E-mail the corresponding author} ; Majid Golkar^b ; Mahdi Behdani^c ; Gashin Rezaei^a ; Leila Ghazizadeh^a ; Mohsen Abolhassani^d ; ^{mabolhassani@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Mohammad Ali Shokrgozar^a ; ^{mashokrgozar@pasteur.ac.ir" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Antibody engineering ; AML ; Leukemic cancer stem cells ; Bivalent scFv (biscFv) ; CD123
• 刊名：Analytical Biochemistry
• 出版年：2016
• 出版时间：15 October 2016
• 年：2016
• 卷：511
• 期：Complete
• 页码：27-30
• 全文大小：533 K

文摘

Antibody engineering involves a range of custom modifications of immunoglobulins to improve their affinity, valency, and pharmacokinetics, ensuring a better target therapy achievement. A number of therapeutic antibodies have been used for cell surface receptor blockage, interfering with the ligand binding and inhibiting receptor-driven activation of cells. Here we describe the construction and characterization of a recombinant bivalent single-chain Fv (biscFv) that targets CD123. On conversion of anti-CD123 scFv to biscFv format, the recognition of the cognate ligand is not altered. Moreover, the increased overall efficacy of the anti-CD123 biscFv in binding and inhibition of CD123/IL-3 (interleukin-3) interactions in TF-1 cells is demonstrated.